Nimotuzumab, as one of the monoclonal antibodies against EGFR, has been found to have an effect on reducing tumor volumes despite its role in increasing overall survival in patients with locally advanced nasopharyngeal carcinoma (NPC) while in combination with other treatment regimens is still debatable. Here, EGFR is linked to nasopharyngeal carcinoma.